he s confident in the success of ferrari s ipo as it is about to be priced at 48 to $52 a share. japan post shows the ipo at a top end of the price range in a listing that creates a combined value of $65 billion. all right. so here we go. less than 7% but you know what, 6.8, not bad. 6.9 was better than 6.8% forecast in the world s second largest economy. the weakest read we ve seen for chinese gdp in more than six years. you have to go back to the global financial crisis in 2009. however, a number of analysts and economists were forecasting 6.8, will. take the 6.9 and to the good with the bad. people surprised with the positivity there. overall, a series of down beat data has raised further support measures to prop up the economy. weak than than expected growth and fixed asset investment came in below forecast. retail sales, that was a bright spot rising slightly above expectations in september. let s get out to uneunice. she joins us live from beijing. reporter: tha
dow closing down 31 points. nasdaq droroing 0.5%. this morning we learned in a total blockbuster of a deal. that pfizer is trying to reinvent itself by buying allergan, agn, to be more efficient with overseas capital. allergan gives them a way to do that. it cost them a pretty penny, the company is confident this is a good one. allergan has an excellent vaccine and cancer franchises, includudg their benchmark drug, botox, which they haven t raised the price up, while simultaneously keeping up with new uses for the darn thing, past wrinkles and migraines. perhaps they can run into a new form of company with this merger and the cash flow they had. that s what the hope is. in the meaeaime you re being paid to wave dividends that nets 3.5%. the market doesn t like this. absolutely doesn t like this deal. for real allergan shareholders because it s delighted with phaser before it closes. and potential government challenge over the tax avoidance scheme. we believed in brett saund
botox, which they haven t raised the price up, while simultaneously keeping up with new uses for the darn thing, past wrinkles and migraines. perhaps they can run into a new form of company with this merger and the cash flow they had. that s what the hope is. in the meantime you re being paid to wave dividends that nets 3.5%. the market doesn t like this. absolutely doesn t like this deal. for real allergan shareholders because it s delighted with phaser before it closes. and potential government challenge over the tax avoidance scheme. we believed in brett saunders aspirational earnings estimate. the ceo laid that over and over again, including on mad money. that s something that frankly is no longer a factor. i still believe in brent saunders. still believe in allergan money, more convoluted. the cut and run crowd and arbitrators will think otherwise, but totally understand the frustration of allergan shareholders who were really pretty furious, come to think of it. bu
nasdaq dropping 0.5%. this morning we learned in a total blockbuster of a deal. that pfizer is trying to reinvent itself by buying allergan, agn, to be more efficient with overseas capital. allergan gives them a way to do that. it cost them a pretty penny, the company is confident this is a good one. allergan has an excellent vaccine and cancer franchises, including their benchmark drug, botox, which they haven t raised the price up, while simultaneously keeping up with new uses for the darn thing, past wrinkles and migraines. perhaps they can run into a new form of company with this merger that s what the hope is. in the meantime you re being paid to wave dividends that nets 3.5%. the market doesn t like this. absolutely doesn t like this deal. for real allergan shareholders because it s delighted with phaser before it closes. and potential government challenge over the tax avoidance scheme. we believed in brett saunders aspirational earnings estimate. the ceo laid that o
Quanos Connect Strengthens Its Position as an Industry Event for Technical Writing, Aftersales, and Service with Quanos Connect 2024 presseschleuder.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from presseschleuder.com Daily Mail and Mail on Sunday newspapers.